Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Philogen SpA ( (IT:PHIL) ).
Philogen S.p.A. announced an update on its share buyback program, revealing the purchase of 1,800 shares between May 19 and May 23, 2025, at an average price of Euro 22.30 per share, totaling Euro 40,140.00. Since the program’s inception, the company has acquired 13,952 shares, representing 0.0344% of its share capital, with a total value of Euro 309,433.85. This move is part of Philogen’s strategy to manage its capital structure and potentially increase shareholder value, reflecting confidence in its ongoing operations and future prospects.
The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR25.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.
More about Philogen SpA
Philogen is an Italian-Swiss biotechnology company specializing in the research and development of pharmaceutical products aimed at treating high mortality diseases. The company focuses on discovering and developing targeted anti-cancer drugs using high-affinity ligands for tumor markers, primarily through tumor targeting and vascular targeting strategies. Philogen aims to generate, develop, and commercialize innovative products for diseases lacking satisfactory therapies, leveraging proprietary technologies, expertise in drug development, and a robust portfolio of patents.
YTD Price Performance: 14.87%
Average Trading Volume: 9,439
Technical Sentiment Signal: Buy
Current Market Cap: €655M
For detailed information about PHIL stock, go to TipRanks’ Stock Analysis page.